Safety and feasibility of outpatient chimeric antigen receptor (CAR) T-cell therapy: experience from a tertiary care center

Bone Marrow Transplant. 2022 Jun;57(6):1025-1027. doi: 10.1038/s41409-022-01664-z. Epub 2022 Apr 11.

Affiliations

¹ Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Azra-borogovac@ouhsc.edu.
² Hematology-Oncology Section, Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
³ Hematology-Oncology Section, Department of Medicine, University of Augusta, Augusta, GA, USA.

^# Contributed equally.

No abstract available

Publication types

Letter

MeSH terms

Cell- and Tissue-Based Therapy
Feasibility Studies
Humans
Immunotherapy, Adoptive / adverse effects
Outpatients
Receptors, Antigen, T-Cell / therapeutic use
Receptors, Chimeric Antigen* / therapeutic use
Tertiary Care Centers

Substances

Receptors, Antigen, T-Cell
Receptors, Chimeric Antigen